The STK11 mutation defines a special subtype of lung adenocarcinoma (LUAD) patients, and emerging evidences suggested that STK11 alterations may be prognostic and/or predictive of therapeutic response, particularly in immune- and targeted therapy, and some studies demonstrated that loss of function caused by STK11 mutation was highly correlated with poor outcomes of NSCLC (9–11). The gene discussed is STK11; the disease is non-small cell lung carcinoma.